spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  fampridine 

 HSMN NewsFeed - 17 May 2016
Catalyst Pharmaceuticals Announces Reduction in Workforce as Part of Operating Expense Management Plan
Biopharmaceuticals
 HSMN NewsFeed - 26 Feb 2016
Catalyst Pharmaceuticals Appoints Brian Elsbernd as Senior Vice President of Legal and Compliance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Feb 2016
Catalyst Pharmaceuticals Receives "Refusal to File" Letter From the FDA on Its NDA for Firdapse
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Jan 2016
Acorda to Acquire Biotie Therapies
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 20 Jul 2015
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jan 2015
Catalyst Pharmaceuticals Appoints David D. Muth, Executive Vice President, Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Sep 2014
Catalyst Pharmaceuticals Appoints David D. Muth as Executive Vice President, Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 May 2014
Acorda Therapeutics Appoints Andrew Hindman as Chief Business Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jan 2014
BioMarin Announces Selection of Factor VIII Gene Therapy Drug Development Candidate BMN 270 for the Treatment of Hemophilia A
Biopharmaceuticals
 HSMN NewsFeed - 7 Oct 2013
Acorda Therapeutics Appoints Michael Rogers Chief Financial Officer; David Lawrence Named Chief of Business Operations
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 20 Sep 2013
Vital Therapies, Inc. Expands Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Sep 2013
BioMarin Appoints Richard Ranieri as Senior Vice President, Human Resources and Corporate Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jan 2013
Acorda Therapeutics Announces Department of Defense Contract to Support Study of AC105 in Acute Spinal Cord Injury
Biopharmaceuticals Neurology Neurosurgery
 HSMN NewsFeed - 21 Dec 2012
Acorda Therapeutics Announces Completion of Neuronex, Inc. Acquisition
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 9 Oct 2012
Acorda Therapeutics Names Jane Wasman President, International
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Sep 2012
BioMarin Names Jeff Ajer Senior Vice President, Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2011
Acorda Therapeutics Announces Enrique Carrazana, M.D. Joins Company as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 May 2011
European Medicines Agency’s Committee for Medicinal Products for Human Use Issues Positive Opinion on Marketing Authorisation Application for FAMPYRA
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 16 May 2011
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 23 Sep 2010
BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Aug 2010
BioMarin Acquires ZyStor Therapeutics, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Jul 2010
Acorda Therapeutics Announces Douglas Kargman Joins as Vice President of Drug Safety
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Apr 2010
BioMarin Launches Firdapse in the European Union
Biopharmaceuticals
 HSMN NewsFeed - 22 Feb 2010
Acorda Therapeutics Announces Adrian L. Rabinowicz Joins as Senior Vice President of Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Feb 2010
BioMarin to Acquire LEAD Therapeutics
Biopharmaceuticals Mergers & Acquisitions Oncology
 HSMN NewsFeed - 3 Feb 2010
Acorda Therapeutics Announces Pricing and Patient Assistance Programs for AMPYRA (dalfampridine)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Jan 2010
Acorda Therapeutics Announces Lauren Sabella Joins as Executive Vice President of Commercial Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jan 2010
Biogen Idec Issues Statement on U.S. Approval of AMPYRA (dalfampridine)
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 22 Jan 2010
Acorda Therapeutics Announces FDA Approval of AMPYRA (dalfampridine) to Improve Walking in People with Multiple Sclerosis - Demonstrated by Increases in Walking Speed
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 30 Nov 2009
FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Jul 2009
Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 20 Sep 2008
Acorda Therapeutics Presents Additional Data from Second Positive Phase 3 Study of Fampridine-SR at World Congress on Treatment and Research in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Jun 2008
Acorda Therapeutics Announces Positive Data from Second Phase 3 Study of Fampridine-SR on Walking Ability in People with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Apr 2008
Acorda Therapeutics Names John Librie Senior Vice President, Sales and Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Feb 2008
Acorda Therapeutics Announces Acquisition of Aminopyridine and Pre-Clinical Assets from Neurorecovery, Inc.
Biopharmaceuticals Acquisitions Neurology
 HSMN NewsFeed - 20 Jul 2007
Acorda Therapeutics Announces Resignation of Mary Fisher
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jun 2007
Acorda Therapeutics Begins Second Phase 3 Clinical Trial of Fampridine-SR in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 May 2007
Acorda Therapeutics and FDA Reach Agreement on Special Protocol Assessment for Second Phase 3 Study of Fampridine-SR in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 May 2007
Acorda Therapeutics Presents Data from its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy of Neurology Meeting
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Feb 2007
Acorda Therapeutics Responds to Third Point Letter
Biopharmaceuticals
 HSMN NewsFeed - 17 Oct 2006
Acorda Therapeutics Announces Expansion of Zanaflex Capsules(TM) Sales Force to 65
Biopharmaceuticals
 HSMN NewsFeed - 4 Oct 2006
Acorda Therapeutics Announces $31.5 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 25 Sep 2006
Acorda Therapeutics Announces Positive Results of Phase 3 Study of Fampridine-SR on Walking in People with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Mar 2006
Acorda Therapeutics(R) Announces Completion of Enrollment in Fampridine-SR Clinical Trial in Multiple Sclerosis and Expansion of Sales Force for Zanaflex Capsules(TM)
Biopharmaceuticals Neurology
Return to NewsFeed  

 Additional items found! 9

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 9 additional stories matching:
fampridine
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.